In another study [39], Cediranib, a potent inhibitor of VEGFRs, which also targets KIT and PDGFRA, was shown to induce a significant reduction of U251 glioma cells in S phase and a higher percentage of apoptotic cells. This evidence concerns the gene KIT and central nervous system cancer.